Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 166,000 Shares of Stock

Posted by Geri Gentry on Aug 7th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. This trade represents a 71.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Dianthus Therapeutics Price Performance

DNTH stock traded down $1.00 during trading hours on Friday, reaching $108.92. The stock had a trading volume of 570,177 shares, compared to its average volume of 974,445. The stock has a market capitalization of $5.95 billion, a PE ratio of -26.25 and a beta of 1.22. The stock has a 50-day simple moving average of $94.40 and a 200 day simple moving average of $80.45. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of recent analyst reports. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Truist Financial increased their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $124.27.

Read Our Latest Research Report on DNTH

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares during the period. UBS Group AG increased its position in Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares during the period. SG Americas Securities LLC bought a new position in Dianthus Therapeutics during the fourth quarter worth about $765,000. BNP Paribas Financial Markets raised its stake in Dianthus Therapeutics by 1,275.3% in the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after purchasing an additional 441,156 shares in the last quarter. Finally, SummitTX Capital L.P. raised its stake in Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.